Last reviewed · How we verify
YSPSL
At a glance
| Generic name | YSPSL |
|---|---|
| Also known as | rPSGL-Ig, recombinant P-selectin glycoprotein ligand-Ig |
| Sponsor | Y's Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation (PHASE2)
- YSPSL for Prevention of Delayed Graft Function Part B (PHASE1, PHASE2)
- YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation (PHASE2)
- YSPSL for Prevention of Delayed Graft Function Part A
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YSPSL CI brief — competitive landscape report
- YSPSL updates RSS · CI watch RSS
- Y's Therapeutics, Inc. portfolio CI